Marinus Pharmaceuticals Inc R&D Day Transcript
Good morning, and welcome to the Marinus Pharmaceuticals 2021 R&D Day. My name is Sasha Damouni Ellis, and I'm Vice President, Corporate Affairs and Investor Relations at Marinus. This morning, members of our leadership team will discuss the company's clinical development program, pipeline expansion opportunities, commercial strategy and reformulation initiatives.
Our CEO, Scott Braunstein, will lead with an overview of recent accomplishments, upcoming milestones and overall corporate goals. Dr. Joe Hulihan, our Chief Medical Officer, will discuss our IV ganaxolone clinical development program as well as updates across the continuum and status epilepticus. Dr. Alex Aimetti, Vice President, Scientific Affairs, will discuss our oral ganaxolone clinical development strategy, including commentary on plans for the upcoming Phase III clinical trials in tuberous sclerosis complex. Dr. Ian Miller, Vice President, Clinical Development, will give an overview of the unmet need in pediatric epilepsies and potential
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |